Piperidine → 4-(1-Ethyl-3-methoxy-5-methyl-1H-pyrazol-4-yl)piperidine
反応式
C(OC([N:8]1[CH2:13][CH2:12][CH:11]([C:14]2[C:15]([O:22][CH3:23])=[N:16][N:17]([CH2:20][CH3:21])[C:18]=2[CH3:19])[CH2:10][CH2:9]1)=O)(C)(C)C.N1CCCCC1>>[CH2:20]([N:17]1[C:18]([CH3:19])=[C:14]([CH:11]2[CH2:12][CH2:13][NH:8][CH2:9][CH2:10]2)[C:15]([O:22][CH3:23])=[N:16]1)[CH3:21]参加物
3
実験手順
The title compound was prepared from 1-tert-butoxycarbonyl-4-(1-ethyl-3-methoxy-5-methyl-(1H)-pyrazol-4-yl)piperidine (Step E) using a procedure analogous to that described for Piperidine 14, Step F. 1H-NMR (500 MHz) δ 1.33 (t, J=7.2, 3H), 1.61–1.64 (m, 2H), 1.89–1.98 (m, 2H), 2.17 (s, 3H), 2.42–2.49 (m, 1H), 2.68–2.73 (m, 2H), 2.90 (m, 1H),3.19–3.22 (m, 2H), 3.87 (s, 3H), 3.92 (q, J=7.2, 2H).
出典と根拠
- ORDレコード
- ord-7f06af718c6644428a2879b2a376e755
- 出典データセット
- uspto-grants-2006_10
- 特許番号
- US07125887B2
反応ノート
読み込み中…